Simbionix USA has settled patent infringement claims from Immersion Corp. , based in San Jose, Calif., by licensing Immersion’s haptics technology for use in its medical procedure simulators.
Immersion Corp. makes technology that interfaces with users through the sense of touch. In April 2008, Immersion sued Simbionix in U.S. District Court for the Northern District of Ohio for infringing on patents that cover its technology.
The two companies have signed a nonexclusive, worldwide license agreement for Immersion’s patent portfolio for use in medical training and simulation, ending the patent infringement case. Terms of the settlement were confidential.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
“This positive development is definitive validation of our licensing strategy and strengthens the value of our intellectual property,” said Craig Vachon, senior vice president and general manager of Immersion, in a Business Wire release. “As a leader in medical simulation, Simbionix understands the critical value of haptics in engaging a clinician’s sense of touch for care giving.”
The agreement enables Immersion and Simbionix to work together.
“We’re pleased with this successful resolution — the agreement lets us get past the cost and distraction of dispute, and allows us to focus on our continued record growth and acceptance of Simbionix products by the simulation industry and professional societies and medical training centers around the world,” said Gary Zamler, chief executive officer of Simbionix, in the release.
The agreement could open doors for Simbionix, the Cleveland company that makes simulators to train doctors and others how to do medical procedures, as well as rehearse procedures using patients’ medical information.
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
“We are excited about the new agreement, which demonstrates the ability of two leading technology companies to push the boundaries of simulation technology,” said Ran Bronstein, Simbionix founder and president, in the release.